MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 462018 | Name: Dalargin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dalargin is a endogenous opioid peptide leucine-encephalin. It exhibits a pronounced cytoprotective and regeneratory action and may take an important place in treating the internal organ diseases.

Chemical Structure

Dalargin
Dalargin
CAS#81733-79-1

Theoretical Analysis

MedKoo Cat#: 462018

Name: Dalargin

CAS#: 81733-79-1

Chemical Formula: C35H51N9O8

Exact Mass: 725.3861

Molecular Weight: 725.85

Elemental Analysis: C, 57.92; H, 7.08; N, 17.37; O, 17.63

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Dalargin; Tageflar; BRN 4287455; Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine
IUPAC/Chemical Name
L-Arginine, N(sup 2)-(N-(N-(N-(L-tyrosyl-D-alanyl)glycyl)-L-phenylalanyl)-L-leucyl)-
InChi Key
GDPHPXYFLPDZGH-XBTMSFKCSA-N
InChi Code
InChI=1S/C35H51N9O8/c1-20(2)16-27(32(49)43-26(34(51)52)10-7-15-39-35(37)38)44-33(50)28(18-22-8-5-4-6-9-22)42-29(46)19-40-30(47)21(3)41-31(48)25(36)17-23-11-13-24(45)14-12-23/h4-6,8-9,11-14,20-21,25-28,45H,7,10,15-19,36H2,1-3H3,(H,40,47)(H,41,48)(H,42,46)(H,43,49)(H,44,50)(H,51,52)(H4,37,38,39)/t21-,25+,26+,27+,28+/m1/s1
SMILES Code
N=C(N)NCCC[C@@H](C(O)=O)NC([C@H](CC(C)C)NC([C@H](CC1=CC=CC=C1)NC(CNC([C@@H](C)NC([C@H](CC2=CC=C(O)C=C2)N)=O)=O)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 725.85 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Activity profiles of dalargin and its analogues in μ-, δ- and κ-opioid receptor selective bioassays Nevena Pencheva, Jan Pospišek, Linda Hauzerova, Tomislav Barth, Peter Milanov Br J Pharmacol. 1999 Oct; 128(3): 569–576. doi: 10.1038/sj.bjp.0702825 PMCID: PMC1571668 2: Improvement of Peptide Affinity and Stability by Complexing to Cyclodextrin-Grafted Ammonium Chitosan Andrea Cesari, Alessandra Recchimurzo, Angela Fabiano, Federica Balzano, Nicolò Rossi, Chiara Migone, Gloria Uccello-Barretta, Ylenia Zambito, Anna Maria Piras Polymers (Basel) 2020 Feb; 12(2): 474. Published online 2020 Feb 19. doi: 10.3390/polym12020474 PMCID: PMC7077720 3: Influence of Chronobiology on the Nanoparticle-Mediated Drug Uptake into the Brain Jörg Kreuter Pharmaceutics. 2015 Mar; 7(1): 3–9. Published online 2015 Feb 3. doi: 10.3390/pharmaceutics7010003 PMCID: PMC4381197 4: The Bactericidal Activity of Temporin Analogues Against Methicillin Resistant Staphylococcus aureus Anna Golda, Paulina Kosikowska-Adamus, Aleksandra Kret, Olena Babyak, Kinga Wójcik, Ewelina Dobosz, Jan Potempa, Adam Lesner, Joanna Koziel Int J Mol Sci. 2019 Oct; 20(19): 4761. Published online 2019 Sep 25. doi: 10.3390/ijms20194761 PMCID: PMC6801822 5: Approaches to CNS Drug Delivery with a Focus on Transporter-Mediated Transcytosis Rana Abdul Razzak, Gordon J. Florence, Frank J. Gunn-Moore Int J Mol Sci. 2019 Jun; 20(12): 3108. Published online 2019 Jun 25. doi: 10.3390/ijms20123108 PMCID: PMC6627589 6: Multifunctional Polymeric Nanoplatforms for Brain Diseases Diagnosis, Therapy and Theranostics Shahryar Shakeri, Milad Ashrafizadeh, Ali Zarrabi, Rasoul Roghanian, Elham Ghasemipour Afshar, Abbas Pardakhty, Reza Mohammadinejad, Anuj Kumar, Vijay Kumar Thakur Biomedicines. 2020 Jan; 8(1): 13. Published online 2020 Jan 13. doi: 10.3390/biomedicines8010013 PMCID: PMC7168063 7: Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists Leonid N Maslov, Igor Khaliulin, Peter R. Oeltgen, Natalia V. Naryzhnaya, Jian‐Ming Pei, Stephen A. Brown, Yury B. Lishmanov, James M. Downey Med Res Rev. 2016 Sep; 36(5): 871–923. Published online 2016 May 16. doi: 10.1002/med.21395 PMCID: PMC5082499 8: Polymeric Nanoparticles for the Treatment of Malignant Gliomas Basant Salah Mahmoud, Ali Hamod AlAmri, Christopher McConville Cancers (Basel) 2020 Jan; 12(1): 175. Published online 2020 Jan 10. doi: 10.3390/cancers12010175 PMCID: PMC7017235 9: Agile Delivery of Protein Therapeutics to CNS Xiang Yi, Devika S. Manickam, Anna Brynskikh, Alexander V. Kabanov J Control Release. Author manuscript; available in PMC 2015 Sep 28.Published in final edited form as: J Control Release. 2014 Sep 28; 0: 637–663. Published online 2014 Jun 21. doi: 10.1016/j.jconrel.2014.06.017 PMCID: PMC4142106 10: Enabling nanomaterial, nanofabrication and cellular technologies for nanoneuromedicines Surya K. Mallapragada, Timothy M. Brenza, JoEllyn M. McMillan, Balaji Narasimhan, Donald S. Sakaguchi, Anup D. Sharma, Svitlana Zbarska, Howard E. Gendelman Nanomedicine. Author manuscript; available in PMC 2016 Apr 1.Published in final edited form as: Nanomedicine. 2015 Apr; 11(3): 715–729. Published online 2015 Jan 31. doi: 10.1016/j.nano.2014.12.013 PMCID: PMC4628726

View History

NSC89933

NSC89933